

Jose Rosas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/86043/publications.pdf>

Version: 2024-02-01

20
papers

779
citations

840776

11
h-index

794594

19
g-index

20
all docs

20
docs citations

20
times ranked

1119
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary Sjögren Syndrome in Spain. <i>Medicine (United States)</i> , 2008, 87, 210-219.	1.0	459
2	Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1693-1696.	0.9	71
3	Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study. <i>Reumatología Clínica</i> , 2022, 18, 150-156.	0.5	44
4	Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study. <i>Rheumatology</i> , 2018, 57, 688-693.	1.9	33
5	Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis. <i>Patient Preference and Adherence</i> , 2013, 7, 961.	1.8	26
6	Obesity decreases clinical efficacy and levels of adalimumab in patients with ankylosing spondylitis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 145-148.	0.8	26
7	Whipple's disease diagnosed during anti-tumor necrosis factor alpha treatment: two case reports and review of the literature. <i>Journal of Medical Case Reports</i> , 2015, 9, 165.	0.8	20
8	Serum drug levels of biologic agents in the management of rheumatoid arthritis and spondyloarthritis: a systematic review. <i>Rheumatology International</i> , 2018, 38, 975-983.	3.0	15
9	Clinical relevance of monitoring serum adalimumab levels in axial spondyloarthritis. <i>Rheumatology International</i> , 2019, 39, 841-849.	3.0	15
10	Clinical relevance of monitoring serum levels of adalimumab in patients with rheumatoid arthritis in daily practice. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, 942-8.	0.8	14
11	SJGREN-SER: Registro nacional de pacientes con síndrome de Sjögren primario de la Sociedad Española de Reumatología: objetivos y metodología. <i>Reumatología Clínica</i> , 2016, 12, 184-189.	0.5	12
12	Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study. <i>Reumatología Clínica (English Edition)</i> , 2022, 18, 150-156.	0.3	12
13	ESSDAI activity index of the SJGREN-SER cohort: analysis and comparison with other European cohorts. <i>Rheumatology International</i> , 2019, 39, 991-999.	3.0	9
14	Real-World Treatment Patterns and Clinical Outcomes of Baricitinib in Rheumatoid Arthritis Patients in Spain: Results of a Multicenter, Observational Study in Routine Clinical Practice (The ORBIT-RA) <i>Journal of Rheumatology</i> , 2021, 48, 1010-1016.	3.0	8
15	Estudio comparativo de las 2 versiones de un inmunoanálisis comercializado para la monitorización terapéutica de adalimumab en artritis reumatoide. <i>Reumatología Clínica</i> , 2014, 10, 105-108.	0.5	5
16	Aspectos prácticos de la medición de los niveles de fármacos biológicos y de anticuerpos antifármaco en artritis reumatoide y espondiloartritis. <i>Reumatología Clínica</i> , 2020, 16, 378-385.	0.5	5
17	Agreement in assessment of infliximab and adalimumab levels in rheumatoid arthritis: interlaboratory and interassay comparison. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 617-23.	0.8	4
18	Practical aspects of biological trough levels and antidrug antibodies in rheumatoid arthritis and spondyloarthritis. <i>Reumatología Clínica (English Edition)</i> , 2020, 16, 378-385.	0.3	1

#	ARTICLE	IF	CITATIONS
19	Eficacia y seguridad de baricitinib en pacientes con artritis reumatoide y respuesta inadecuada a FAME convencionales sint�ticos o biol�gicos: datos de un registro local. Reumatolog�a Cl�nica, 2020, 18, 188-188.	0.5	1
20	Efficacy and Safety of Baricitinib in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic DMARDs and/or Biological DMARDs: Data from a Local Registry. Reumatolog�a Cl�nica (English Edition), 2022, 18, 188-189.	0.3	0